Accelerated Hyperfractionated Radiotherapy Combined with Induction and Concomitant Chemotherapy for Inoperable Non-small-cell Lung Cancer: Impact of Total Treatment Time

References

• Shepherd FA. Treatment of advanced non-small cell lung cancer. Semin Oncol 1994; 21: 7–18.
   PubMedGoogle Scholar
• Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiother-apy. Report by the Radiation Therapy Oncology Group. Cancer 1987; 59: 1874–81.
   Google Scholar
• Wilson GD, McNally NJ, Dische S, Bennett MH. Cell prolif-eration in human tumours measured by in vivo labelling with bromodeoxyuridine. Br J Cancer 1988; 6: 419–22.
   Google Scholar
• Saunders MI, Dische S. Continuous, hyperfractionated, accel-erated radiotherapy (CHART) in non-small-cell carcinoma of the bronchus. Int .1- Radiat Oncol Biol Phys 1990; 19: 1211–5.
   PubMed Web of Science ®Google Scholar
• Saunders MI, Dische S, Barret A, et al. Randomised multi-centre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. Br J Cancer 1996; 73: 1455–62.
   PubMed Web of Science ®Google Scholar
• Koukourakis M, Hlouverakis G, Kosma L, et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int .1- Radiat Oncol Biol Phys 1996; 34: 315–22.
   PubMed Web of Science ®Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 ran-domised clinical trials. Br Med J 1995; 311: 899–909.
   PubMed Web of Science ®Google Scholar
• Dewit L. Combined treatment of radiation and cis-di-aminedichloroplatinum (II): A review of experimental and clinical data. Int .1- Radiat Oncol Biol Phys 1987; 13: 403–26.
   PubMed Web of Science ®Google Scholar
• Schaake-Koning C, van den Bogaert W, Dalesio 0, et al. Effects of concomitant cisplatin and radiotherapy on inopera-ble non-small-cell lung cancer. N Engl J Med 1992; 326: 524–30.
   Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyper-fractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomised study. J Clin Oncol 1996; 14: 1065–70.
   PubMed Web of Science ®Google Scholar
• Brindle JS, Shaw EG, Su JQ, et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage III non-small cell lung carcinoma. Cancer 1993; 72: 405–9.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Handbook for reporting the results of cancer treatment. Vol 48. Geneva, 1979.
   Google Scholar
• Peto R, Dike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation for each patient. Analysis and examples. Br J Cancer 1977; 35: 1–39.
   PubMed Web of Science ®Google Scholar
• Brodin 0, Nou E, Mercke C, et al. Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. Eur J Cancer 1996; 32A: 1893–900.
   Google Scholar
• Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: Seven year follow-up of cancer and leukemia Group B 8433 trial. J Natl Cancer Inst 1996; 88: 1210–5.
   PubMed Web of Science ®Google Scholar
• Byhardt RW, Martin L, Pajak TF, et al. The influence of field size and other treatment factors on pulmonary toxicity fol-lowing hyperfractionated irradiation for inoperable non-small cell lung cancer-analysis of a radiation therapy oncology group protocol. Int .1- Radiat Oncol Biol Phys 1993; 27: 537–44.
   PubMedGoogle Scholar
• Le Chevallier T, Arriagada R, Quoix E, et al. Radiotherapy alone vs. combined chemotherapy and radiotherapy in nonre-sectable nonsmall cell lung cancer: first analysis of a random-ized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417–23.
   Google Scholar
• Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: RTOG protocol 91-06. J Clin Oncol 1996; 14: 1055–64.
   PubMedGoogle Scholar
• Furuse K, Fukuoka Y, Takada H, et al. A randomised phase III study of concurrent versus sequential thoracic radiother-apy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer: prelimi-nary analysis. Proceedings of ASCO 1997; 16: 459a.
   Google Scholar
• Shaw EG, McGinnis WL, Jett JR, et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung. J Natl Cancer Inst 1993; 85: 321–3.
   PubMedGoogle Scholar
• Reboul F, Brewer Y, Vincent P, et al. Concurrent cisplatin, etoposide and radiotherapy for unresectable stage III nons-mall cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys 1996; 35: 343–50.
   PubMedGoogle Scholar
• Pitsch J, Berson AM, Malamud S, et al. Chemoradiation in advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1995; 33: 183–8.
   PubMedGoogle Scholar
• Alberto P, Mirimanoff RO, Mermillod B, et al. Rapidly alternating combination of cisplatin-based chemotherapy and hyperfractionated accelerated radiotherapy in split course for stage IIIA and stage IIIB non-small-cell lung cancer: results of a phase I-II study by the GOTHA group. Eur J Cancer 1995; 31A: 342–8.
   PubMedGoogle Scholar
• Byhardt RW, Scott CB, Ettinger DS, et al. Concurrent hyper-fractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Cancer 1995; 75: 2337–44.
   PubMedGoogle Scholar
• Le Pe'choux C, Arriagada R, Le Chevalier T, et al. Concur-rent cisplatin-vindesine and hyperfractionated thoracic radio-therapy in locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1996; 35: 519–25.
   Google Scholar
• Ball D, Bishop J, Smith J, et al. Phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients. Int J Radiat Oncol Biol Phys 1995; 31: 267–72.
   PubMedGoogle Scholar
• Ball D, Bishop J, Smith J, et al. A phase III study of conventional and accelerated radiotherapy with and without carboplatin in unresectable non small cell lung cancer. Radio-therapy and Oncology 1996, 40 (Suppl 1): S61, 231.
   Google Scholar
• Sause WT, Scott C, Taylor S, et al. RTOG 88-08 and ECOG 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87: 198–205.
   PubMed Web of Science ®Google Scholar
• Feld R, Borges M, Giner V, et al. Prognostic factors in non-small cell lung cancer. Lung Cancer 1994; 11 (Suppl 3): 19–23.
   PubMedGoogle Scholar